FFRct vs AI-CVD
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
FFRct is a diagnostic tool focused on providing detailed functional assessment of coronary artery disease from dedicated CCTA scans to guide treatment strategies. In contrast, AI-CVD specializes in opportunistic screening for a broader range of cardiovascular and multisystem risks by analyzing existing CT scans without requiring additional imaging. They address different needs in the patient care pathway, with FFRct offering in-depth diagnostic insights and AI-CVD enabling early, broad risk detection.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
FFRct is a non-invasive AI-powered diagnostic tool that creates personalized 3D models of coronary arteries from CCTA scans to assess blood flow and aid in diagnosing coronary artery disease (CAD), helping to guide treatment strategies and revascularization decisions. AI-CVD is an FDA-cleared, AI-powered quantitative imaging platform that performs opportunistic screening for cardiovascular and multisystem diseases using existing CT scans, enabling early detection of hidden health risks.
FFRct requires Coronary CT Angiography (CCTA) scans to generate personalized 3D digital models of coronary arteries. AI-CVD utilizes existing chest and abdominal CT scans for opportunistic screening, without requiring additional imaging, radiation, contrast, or workflow disruption.
FFRct analyzes blood flow and identifies areas of narrowing by generating FFRct values, integrating anatomical and physiological data from CCTA to determine the physiological significance of lesions. AI-CVD provides automated CT-derived anatomical and density-based measurements, including Coronary Artery Calcium (CAC) scoring, aortic wall, aortic valve, and mitral valve calcium analysis, cardiac chamber volumetry, epicardial fat volumetry, and aorta and pulmonary artery sizing.
FFRct processes CCTA data through a cloud-based system with a local Virtual Appliance for data transfer. AI-CVD is a cloud-based platform that performs opportunistic screening using existing chest and abdominal CT scans, explicitly stating no additional imaging, radiation, contrast, or workflow disruption.
The CMS payment rate for FFRct Analysis is $1,017 for 2025, with commercial payer rates varying. For AI-CVD, pricing information requires contacting the vendor, and no specific reimbursement rates are provided in the given facts.
FFRct is primarily targeted towards Cardiology and Radiology specialties. AI-CVD is relevant to Cardiology, Pulmonology, and Radiology, as it screens for cardiovascular and multisystem diseases from chest and abdominal CT scans.